Hepatitis Monthly

Published by: Kowsar

The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy

Seyyed Mohammad Miri 1 , 2 , Heidar Sharafi 2 , 3 , Ali Pouryasin 4 , 5 , Bita Behnava 2 , 3 , Maryam Keshvari 6 , Shima Salimi 3 , Pegah Karimi Elizee 1 and Seyed Moayed Alavian 2 , 3 , *
Authors Information
1 Kowsar Medical Institute, Heerlen, The Netherlands
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
4 Armin Pathobiology Laboratory, Tehran, IR Iran
5 Department of Biology, Arsanjan Branch, Islamic Azad University, Arsanjan, IR Iran
6 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
Article information
  • Hepatitis Monthly: April 2017, 17 (4); e12301
  • Published Online: April 4, 2017
  • Article Type: Research Article
  • Received: February 11, 2017
  • Accepted: February 12, 2017
  • DOI: 10.5812/hepatmon.46539

To Cite: Miri S M, Sharafi H, Pouryasin A, Behnava B, Keshvari M, et al. The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy, Hepat Mon. 2017 ;17(4):e12301. doi: 10.5812/hepatmon.46539.

Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Introduction
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013; 10(9): 553-62[DOI][PubMed]
  • 2. Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon. 2016; 16(9)[DOI][PubMed]
  • 3. Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. Hepat Mon. 2016; 16(12)[DOI][PubMed]
  • 4. Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M. Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol. 2014; 20(19): 5897-902[DOI][PubMed]
  • 5. Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004; 53(10): 1504-8[DOI][PubMed]
  • 6. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016; 16(8)[DOI][PubMed]
  • 7. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology. 2006; 44(1): 15-22[DOI][PubMed]
  • 8. Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F, et al. Occult HCV Infection: The Current State of Knowledge. Iran Red Crescent Med J. 2015; 17(11)[DOI][PubMed]
  • 9. Hubbard JJ, Kottilil S. Extra-hepatic replication of the hepatitis C virus: current issues and future directions. Future Virol. 2011; 6(3): 275-8[DOI]
  • 10. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011; 11(12): 958-9[DOI][PubMed]
  • 11. Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol. 2015; 21(29): 8935-42[DOI][PubMed]
  • 12. Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, et al. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon. 2016; 16(1)[DOI][PubMed]
  • 13. Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, et al. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. Hepat Mon. 2016; 16(6)[DOI][PubMed]
  • 14. Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci. 2016; 21: 72[DOI][PubMed]
  • 15. Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-alpha and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal. 2016; [DOI][PubMed]
  • 16. Pouryasin M, Keshvari M, Sharafi H, Alavian SM, Behnava B, Alavian SE, et al. The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. Hepat Mon. 2016; 16(2)[DOI][PubMed]
  • 17. Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 18. Aalaei-Andabili SH, Behnava B, Salimi S, Sharafi H, Alavian SM. Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis. Hepat Mon. 2014; 14(3)[DOI][PubMed]
  • 19. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012; 12(3): 190-5[DOI][PubMed]
  • 20. Rezaee-Zavareh MS, Ramezani-Binabaj M, Moayed Alavian S. Screening for occult hepatitis C virus infection: Does it need special attention? Hepatology. 2015; 62(1): 321-2[DOI][PubMed]
  • 21. Hanno AFF, Mohiedeen KM, Alshayeb AF, Deghedy A. HCV RNA in peripheral blood mononuclear cells (PBMCs) as a predictor of the response to antiviral therapy in chronic hepatitis C. Alexandria J Med. 2014; 50(4): 317-22[DOI]
  • 22. Cavalheiro Nde P, Filgueiras TC, Melo CE, Morimitsu SR, de Araujo ES, Tengan FM, et al. Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment. Braz J Infect Dis. 2007; 11(5): 471-4[PubMed]
  • 23. Gallegos-Orozco JF, Rakela J, Rosati MJ, Vargas HE, Balan V. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci. 2008; 53(9): 2564-8[DOI][PubMed]
  • 24. Inglot M, Pawlowski T, Szymczak A, Malyszczak K, Zalewska M, Radkowski M. Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Postepy Hig Med Dosw (Online). 2013; 67: 186-91[PubMed]
  • 25. Fujiwara K, Allison RD, Wang RY, Bare P, Matsuura K, Schechterly C, et al. Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology. 2013; 57(2): 483-91[DOI][PubMed]
  • 26. Mohamad HI, El-Bab HK, Kamal AM. HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy. Hepatogastroenterology. 2011; 58(107-108): 932-6[PubMed]
  • 27. Bartolome J, Castillo I, Quiroga JA, Carreno V. Interleukin-28B polymorphisms and interferon gamma inducible protein-10 serum levels in seronegative occult hepatitis C virus infection. J Med Virol. 2016; 88(2): 268-74[DOI][PubMed]
  • 28. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 29. Keshvari M, Pouryasin A, Behnava B, Sharafi H, Hajarizadeh B, Alavian SM. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39(3): 343[DOI][PubMed]
  • 30. Angulo J, Pino K, Pavez C, Biel F, Labbe P, Miquel JF, et al. Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients. J Viral Hepat. 2013; 20(4): 263-72[DOI][PubMed]
  • 31. Pouryasin M, Sharafi H, Behnava B, Alavian SM, Keshvari M, Pouryasin A. A Simple PCR-RFLP Method for Genotyping of IFNL4 rs368234815 Polymorphism in Patients With Chronic Hepatitis C. Lab Med. 2017; 48(1): 51-6[DOI][PubMed]
  • 32. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2): 164-71[DOI][PubMed]
  • 33. Keshvari M, Sharafi H. Interferon-lambda Genetic Variations and Hepatitis C: Yet to be Discovered. Hepat Mon. 2014; 14(5)[DOI][PubMed]
  • 34. Muazzam AG, Qureshi S, Mansoor A, Ali L, Iqbal M, Siddiqi S, et al. Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy. Genet Vaccines Ther. 2011; 9(1): 14[DOI][PubMed]
  • 35. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016; 16(4)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader